Loading
A phase 2 trial of Abiraterone acetate, Apalutamide, Enzalutamide in metastatic cancer and prostate cancer, run by Sun Pharmaceutical Industries Limited, now recruiting.
Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer. is a phase 2 interventional study registered as NCT05422911 by Sun Pharmaceutical Industries Limited, with 192 participants planned, started 2022-08-31 and due to reach its primary completion in 2027-12-31. Interventions recorded: Abiraterone acetate, Apalutamide, Enzalutamide. Conditions listed: Metastatic Cancer, Neoplasm, Prostate, Castrate-sensitive, Castrate-sensitive Prostate Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Abiraterone acetate, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Abiraterone acetate, Enzalutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Apalutamide, Abiraterone acetate, Enzalutamide, Prostate cancer.
Shares Apalutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Apalutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Apalutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Apalutamide, Abiraterone acetate, Prostate cancer.
Shares Apalutamide, Abiraterone acetate, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/